Cipher Pharmaceuticals Inc.

Informe acción TSX:CPH

Capitalización de mercado: CA$204.9m

Cipher Pharmaceuticals Dirección

Dirección controles de criterios 1/4

El CEO de Cipher Pharmaceuticals' es Craig Mull, nombrado en Jul 2019, tiene una permanencia de 4.75 años. posee directamente un 2.98% de las acciones de la empresa, con un valor de CA$6.11M. La antigüedad media del equipo directivo y de la junta directiva es de 3.5 años y 3 años, respectivamente.

Información clave

Craig Mull

Chief Executive Officer (CEO)

US$567.6k

Compensación total

Porcentaje del salario del CEOn/a
Permanencia del CEO4.8yrs
Participación del CEO3.0%
Permanencia media de la dirección3.5yrs
Promedio de permanencia en la Junta Directiva3yrs

Actualizaciones recientes de la dirección

Recent updates

There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Mar 23
There's No Escaping Cipher Pharmaceuticals Inc.'s (TSE:CPH) Muted Earnings Despite A 26% Share Price Rise

Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Mar 22
Weak Statutory Earnings May Not Tell The Whole Story For Cipher Pharmaceuticals (TSE:CPH)

Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

May 14
Here's Why I Think Cipher Pharmaceuticals (TSE:CPH) Is An Interesting Stock

Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)

May 18
Analysts Just Published A Bright New Outlook For Cipher Pharmaceuticals Inc.'s (TSE:CPH)

Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next

Mar 20
Cipher Pharmaceuticals Inc. Just Missed EPS By 37%: Here's What Analysts Think Will Happen Next

Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12%

Jan 26
Industry Analysts Just Upgraded Their Cipher Pharmaceuticals Inc. (TSE:CPH) Revenue Forecasts By 12%

CEO

Craig Mull

4.8yrs

Permanencia

US$567,581

Compensación

Mr. Craig J. Mull has been Chairman of the Board of Directors at Cipher Pharmaceuticals Inc. since June 11, 2019 and its Interim Chief Executive Officer since July 29, 2019, served as its President. Mr. Mu...


Equipo directivo

NombrePosiciónPermanenciaCompensaciónPropiedad
Craig Mull
Interim CEO & Chairman of the Board4.8yrsUS$567.58k2.98%
$ 6.1m
Bryan Jacobs
Chief Financial Officer1.7yrsUS$438.28k0.021%
$ 42.5k
Diane Gajewczyk
Vice President of Scientific & Medical Affairs5.8yrsUS$322.57k0.35%
$ 714.3k
Emilio Presti
Director of Sales & Marketing2.3yrssin datossin datos

3.5yrs

Permanencia media

Equipo directivo experimentado: El equipo directivo de CPH se considera experimentado (3.5 años antigüedad media).


Miembros de la Junta

NombrePosiciónPermanenciaCompensaciónPropiedad
Craig Mull
Interim CEO & Chairman of the Board5.1yrsUS$567.58k2.98%
$ 6.1m
Harold Wolkin
Lead Independent Director7.7yrsUS$60.85k1.51%
$ 3.1m
Douglas Deeth
Independent Directorless than a yearsin datossin datos
Hubert Walinski
Independent Directorless than a yearsin datossin datos

3.0yrs

Permanencia media

Junta con experiencia: La junta directiva de CPH no se considera experimentada (3 años de permanencia promedio), lo que sugiere una nueva junta directiva.